Down syndrome may hold key to new Alzheimer's treatments






Down syndrome may hold key to new Alzheimer's treatments



CHICAGO (Reuters) - In a new lead on Alzheimer's research, Johnson & Johnson is bankrolling a three-year pilot study of people with Down syndrome to identify the early changes that herald dementia, which afflicts up to 75 percent of adults with the condition. The aim is to generate support for a much bigger, public-private partnership funded by drugmakers, advocates and government agencies that will study at least 1,000 people with Down syndrome, tracking them from an early age and eventually testing treatments to keep dementia from developing. ...






Popular posts from this blog

Russian opposition leader charged with theft

Iran unveils long-range drone: state TV

The Censorship Game: Chinese Twitter Will Score User Behavior